Switch theme
Sign up to access all valuation multiples
Zhejiang Huahai Pharmaceutical Co Ltd is engaged in Research & Development, production and sales of multi-dosage preparations, biological drugs, innovative drugs and specialty APIs.
2001
2.9K+
LTM Revenue $1.3B
LTM EBITDA $76.0M
$4.4B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Zhejiang Huahai has a last 12-month revenue (LTM) of $1.3B and a last 12-month EBITDA of $76.0M.
In the most recent fiscal year, Zhejiang Huahai achieved revenue of $1.3B and an EBITDA of $361M.
Zhejiang Huahai expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Zhejiang Huahai valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.3B | XXX | $1.3B | XXX | XXX | XXX |
| Gross Profit | $820M | XXX | $820M | XXX | XXX | XXX |
| Gross Margin | 61% | XXX | 62% | XXX | XXX | XXX |
| EBITDA | $76.0M | XXX | $361M | XXX | XXX | XXX |
| EBITDA Margin | 6% | XXX | 27% | XXX | XXX | XXX |
| EBIT | $222M | XXX | $253M | XXX | XXX | XXX |
| EBIT Margin | 17% | XXX | 19% | XXX | XXX | XXX |
| Net Profit | $160M | XXX | $155M | XXX | XXX | XXX |
| Net Margin | 12% | XXX | 12% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $689M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Zhejiang Huahai's stock price is CNY 17 (or $2).
Zhejiang Huahai has current market cap of CNY 26.1B (or $3.6B), and EV of CNY 31.4B (or $4.4B).
See Zhejiang Huahai trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4.4B | $3.6B | XXX | XXX | XXX | XXX | $0.11 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Zhejiang Huahai has market cap of $3.6B and EV of $4.4B.
Zhejiang Huahai's trades at 3.3x EV/Revenue multiple, and 12.1x EV/EBITDA.
Equity research analysts estimate Zhejiang Huahai's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Zhejiang Huahai has a P/E ratio of 22.6x.
See valuation multiples for Zhejiang Huahai and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3.6B | XXX | $3.6B | XXX | XXX | XXX |
| EV (current) | $4.4B | XXX | $4.4B | XXX | XXX | XXX |
| EV/Revenue | 3.2x | XXX | 3.3x | XXX | XXX | XXX |
| EV/EBITDA | 57.4x | XXX | 12.1x | XXX | XXX | XXX |
| EV/EBIT | 19.6x | XXX | 17.3x | XXX | XXX | XXX |
| EV/Gross Profit | 5.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | 22.6x | XXX | 23.3x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 98.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialZhejiang Huahai's last 12 month revenue growth is 7%
Zhejiang Huahai's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.2M for the same period.
Zhejiang Huahai's rule of 40 is 32% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Zhejiang Huahai's rule of X is 23% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Zhejiang Huahai and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | 7% | XXX | XXX | XXX |
| EBITDA Margin | 6% | XXX | 27% | XXX | XXX | XXX |
| EBITDA Growth | 146% | XXX | -21% | XXX | XXX | XXX |
| Rule of 40 | 32% | XXX | 34% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 23% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 16% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 10% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 43% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Zhejiang Huahai acquired XXX companies to date.
Last acquisition by Zhejiang Huahai was XXXXXXXX, XXXXX XXXXX XXXXXX . Zhejiang Huahai acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Zhejiang Huahai founded? | Zhejiang Huahai was founded in 2001. |
| Where is Zhejiang Huahai headquartered? | Zhejiang Huahai is headquartered in China. |
| How many employees does Zhejiang Huahai have? | As of today, Zhejiang Huahai has 2.9K+ employees. |
| Is Zhejiang Huahai publicy listed? | Yes, Zhejiang Huahai is a public company listed on SHG. |
| What is the stock symbol of Zhejiang Huahai? | Zhejiang Huahai trades under 600521 ticker. |
| When did Zhejiang Huahai go public? | Zhejiang Huahai went public in 2003. |
| Who are competitors of Zhejiang Huahai? | Similar companies to Zhejiang Huahai include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Zhejiang Huahai? | Zhejiang Huahai's current market cap is $3.6B |
| What is the current revenue of Zhejiang Huahai? | Zhejiang Huahai's last 12 months revenue is $1.3B. |
| What is the current revenue growth of Zhejiang Huahai? | Zhejiang Huahai revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of Zhejiang Huahai? | Current revenue multiple of Zhejiang Huahai is 3.2x. |
| Is Zhejiang Huahai profitable? | Yes, Zhejiang Huahai is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Zhejiang Huahai? | Zhejiang Huahai's last 12 months EBITDA is $76.0M. |
| What is Zhejiang Huahai's EBITDA margin? | Zhejiang Huahai's last 12 months EBITDA margin is 6%. |
| What is the current EV/EBITDA multiple of Zhejiang Huahai? | Current EBITDA multiple of Zhejiang Huahai is 57.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
